顽固性高血压的介入治疗肾神经消融_第1页
顽固性高血压的介入治疗肾神经消融_第2页
顽固性高血压的介入治疗肾神经消融_第3页
顽固性高血压的介入治疗肾神经消融_第4页
顽固性高血压的介入治疗肾神经消融_第5页
已阅读5页,还剩29页未读 继续免费阅读

下载本文档

版权说明:本文档由用户提供并上传,收益归属内容提供方,若内容存在侵权,请进行举报或认领

文档简介

顽固性高血压的介入治疗经皮经导管肾神经消融术需要积极稳妥开展临床研究,历史回顾降压药物问世前,上世纪20-50年代,尝试外科切除内脏交感神经治疗高血压,虽然降压有效,中/远期生存率明显提高,但围术期的致死、致残率高,中/远期并发症多。,尽管当代降压药物有长足发展,但仍有部分规范服药的患者血压不能达标,此外:交感神经抑制剂、直接肾素抑制剂、非特异性血管扩张剂、抗高血压疫苗,高血压是全球公共卫生的难题,难治性高血压约占10% -20%,有更高心血管事件风险 Resistant hypertension: Circulation 2008;117: e51026,理论基础的启示:寻找解决办法,Sympathetic nervous system and the kidney in hypertension.,Carotid baroreflex and hypertension,肾交感神经阻断?,颈动脉体迷走神经兴奋?,经导管肾交感神经消融术,Symplicity HTN-1 Three Year and Symplicity HTN-2 One Year Summary,Sustained BP Reductions to Three YearsFirst Symplicity HTN-1 patient treated June 2007 Three year reporting shows no diminishment of effect and impressive long term safetyFor patients that have completed 3 year follow up, 100% have been classified as responders (10 mmHg reduction), while at 6 months 71% of patients were classified as responders.Superior Results Confirmed in Randomised StudySymplicity HTN-2 treatment population shows sustained treatment effect at 12 month follow-upControl cross-over patients also show significant BP reduction,Only the Symplicity renal denervation system has proven safe, superior and sustained BP reductions,Significant, Sustained Blood Pressure Reductions to at Least 3 Years,Expanded results presented at the American College of Cardiology Annual Meeting 2012 (Krum, H.),p 0.01 for from baseline for all time points,Impressive Safety Record Continues in Long Term Follow-up,81 patients with 6-month renal CTA, MRA or duplexNo vascular abnormalities at any site of RF deliveryOne progression of a pre-existing stenosis unrelated to RF treatment (stented without further sequelae)One new moderate stenosis which was not hemodynamically relevant and not treated3 deaths within the follow-up period; all unrelated to the device or therapyNo hypotensive events that required hospitalization There were no observed changes in mean electrolytes or eGFR,Expanded results presented at the American College of Cardiology Annual Meeting 2012 (Krum, H.),Percentage Responders Increases Over Time,Responder was defined as an office SBP reduction 10 mmHg,(n=143),(n=148),(n=144),(n=130),(n=107),(n=59),(n=24),(n=24),Expanded results presented at the American College of Cardiology Annual Meeting 2012 (Krum, H.),Symplicity HTN-2: RDN Superior to Medical Management, Reductions Sustained to 12M, from Baseline to 6 Months (mmHg),Primary Endpoint:84% of RDN patients had 10 mmHg reduction in SBP10% of RDN patients had no reduction in SBP,Systolic,Diastolic,Systolic,Diastolic,Expanded results presented at the American College of Cardiology Annual Meeting 2012 (Esler, M.),RDN (n= 49), from Baseline to 12 Months (mmHg),Systolic,Diastolic,Primary Endpoint (6M post Randomisation),Latest Follow-up(12M post Randomisation),Latest Follow-up:Control crossover (n = 35): -24/-8 mmHg (Analysis on patients with SBP 160 mmHg at 6 M),p 0.01 for from baseline,p 0.01 for difference between RDN and Control,Medication Changes at 6 and 12 Months Post-Renal Denervation,Physicians were allowed to make changes to medicationsOnce the 6 month primary endpoint was reached*,*Further analysis of Medications is ongoing,Symplicity RDN Safety Record Continues to be Strong in Expanded Results,Symplicity HTN-2 Investigators. The Lancet. 2010.,RDNN=47,CrossoverN=35,Treated at Randomisation,Treated after 6-mo follow-up,First-in-Man (AU),Series of Pilot Studies(EU, US & AU),Symplicity HTN-2Initial RCT(EU & AU),SYMPLICITY HTN-3US Pivotal Trial (US),Global SYMPLICITY Registry(Approved Regions),Expand HTN Indication(Approved Regions),Post-Market Registry(US),SYMPLICITY HF,Symplicity HTN-1(n=153),Pilot Studies inNew Indications(Approved Regions),Trials under way,Comprehensive SYMPLICITY Clinical Trial Program follows over 5000 patients across multiple indications,This report,目前的初步结果鼓舞人心作为抑制交感神经过度激活的一种新方法,可能有潜在巨大的临床应用前景。但仍有许多问题尚不明了,积极稳妥的开展相关的临床研究很有必要。,没有即刻评价神经消融技术成功指标Symplicity HTN-1中仅39%消融患者血压控制达标,即达到 BP250秒(2)止疼:射频前经静脉予吗啡和/或芬太尼(3)血管扩张:射频中如发现肾动脉收缩明显,予硝酸甘油100-200ug经导管给药(4)降压:如血压明显升高,予硝普钠经静脉泵入(5)心动过缓/血压下降:阿托品0.5mg和/或多巴胺2-3mg经静脉推注,术中用药与监护,射频导管头端自肾动脉远端至开口,螺旋型后撤,每隔5mm选一个点消融,射频导管头端充分贴壁后,每点传递能量8w,2分钟,一般一条肾动脉要消

温馨提示

  • 1. 本站所有资源如无特殊说明,都需要本地电脑安装OFFICE2007和PDF阅读器。图纸软件为CAD,CAXA,PROE,UG,SolidWorks等.压缩文件请下载最新的WinRAR软件解压。
  • 2. 本站的文档不包含任何第三方提供的附件图纸等,如果需要附件,请联系上传者。文件的所有权益归上传用户所有。
  • 3. 本站RAR压缩包中若带图纸,网页内容里面会有图纸预览,若没有图纸预览就没有图纸。
  • 4. 未经权益所有人同意不得将文件中的内容挪作商业或盈利用途。
  • 5. 人人文库网仅提供信息存储空间,仅对用户上传内容的表现方式做保护处理,对用户上传分享的文档内容本身不做任何修改或编辑,并不能对任何下载内容负责。
  • 6. 下载文件中如有侵权或不适当内容,请与我们联系,我们立即纠正。
  • 7. 本站不保证下载资源的准确性、安全性和完整性, 同时也不承担用户因使用这些下载资源对自己和他人造成任何形式的伤害或损失。

评论

0/150

提交评论